# Amylyx Pharmaceuticals, Inc. (AMLX): MoatMap facts

As of 27 Oct 2026. Research data, not investment advice.

As of 27 Oct 2026, MoatMap's StockRank for Amylyx Pharmaceuticals, Inc. (AMLX) is 30/100, ranked against 24,000+ stocks in 35 markets (Quality 26, Value 23, Momentum 68, each scored against its sector).

- StockRank: 30/100, a percentile across 24,000+ stocks in 35 markets (100 is best).
- Quality 26, Value 23, Momentum 68: each a 0-100 percentile within Healthcare.
- Position: #18,589 overall, #1,618 in Healthcare.
- Listing: United States, NMS; Healthcare / Drug Manufacturers - Specialty & Generic.
- Last close: 27.09 USD on 26 Oct 2026.
- Insider filings, last 180 days: directors bought USD 51K; directors sold USD 4.3M.

Source: https://moatmap.ai/stock/AMLX
How the scores work: https://moatmap.ai/methodology
Does StockRank work? The public record: https://moatmap.ai/decile-tracker